A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Sex: Female

Ages: 19 Years – 54 Years

Phase: PHASE2

Enrollment: 120

Sponsor: Chong Kun Dang Pharmaceutical

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

Eligibility Criteria

Key Inclusion Criteria:Female of age 19-54 yearsClinical Diagnosis of Androgenetic AlopeciaWritten informed consentKey Exclusion Criteria:Other types of Alopecia or other diseases that can cause hair lossClinically significant scalp disease such as seborrheic dermatitis or psoriasisClinically significant hepatic disease, thyroid disease, or mental illness, as determined by the InvestigatorWomen who are pregnant or breastfeedingWomen of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05677438). StuddyBuddy aggregates publicly available trial information.